AR112086A1 - Compuestos heteroaromáticos como inhibidores de vanina - Google Patents
Compuestos heteroaromáticos como inhibidores de vaninaInfo
- Publication number
- AR112086A1 AR112086A1 ARP180101573A ARP180101573A AR112086A1 AR 112086 A1 AR112086 A1 AR 112086A1 AR P180101573 A ARP180101573 A AR P180101573A AR P180101573 A ARP180101573 A AR P180101573A AR 112086 A1 AR112086 A1 AR 112086A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- alkyl
- compounds
- heteroaromatic compounds
- formulas
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Procesos para fabricar estos compuestos, las preparaciones farmacéuticas que contienen estos compuestos y sus métodos de uso. Reivindicación 1: Un compuesto caracterizado por la fórmula (1), en donde A es un grupo de la fórmula (2) ó (3), en donde cada R¹, R², R³, R⁴, R⁵ y R⁶ se selecciona independientemente del grupo que consiste en H, C₁₋₄-alquilo, C₁₋₄-alquilo sustituido con un grupo hidroxilo o halógeno, fenilo y heteroarilo de 5 - 6 miembros, o R¹ y R², R³ y R⁴, o R⁵ y R⁶ juntos forman un carbociclo de 3 - 4 miembros, y en donde B se selecciona del grupo que consiste en las fórmulas (4), (5) y (6), en donde R⁷ es H, C₁₋₃-alquilo, halógeno, C₁₋₃-alcoxi, heteroarilo de 5 - 6 miembros, o R⁷ se selecciona del grupo que consiste en los compuestos de fórmulas (7), (8) y (9), en donde R⁸ se selecciona del grupo que consiste en C₁₋₆-alquilo, C₃₋₆-cicloalquilo y heterociclilo de 3 - 14 miembros, y X es CH₂ ó O; o una sal de aquel aceptable desde el punto de vista farmacéutico.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762518106P | 2017-06-12 | 2017-06-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR112086A1 true AR112086A1 (es) | 2019-09-18 |
Family
ID=62631060
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP180101573A AR112086A1 (es) | 2017-06-12 | 2018-06-11 | Compuestos heteroaromáticos como inhibidores de vanina |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US10364255B2 (es) |
| EP (1) | EP3638680B1 (es) |
| JP (1) | JP6880243B2 (es) |
| KR (1) | KR102607934B1 (es) |
| CN (1) | CN110770242B (es) |
| AR (1) | AR112086A1 (es) |
| AU (1) | AU2018285131B2 (es) |
| BR (1) | BR112019021703A2 (es) |
| CA (1) | CA3066946A1 (es) |
| CL (1) | CL2019003515A1 (es) |
| CO (1) | CO2019013823A2 (es) |
| DK (1) | DK3638680T3 (es) |
| EA (1) | EA039223B1 (es) |
| ES (1) | ES2927021T3 (es) |
| HU (1) | HUE060597T2 (es) |
| IL (1) | IL271104B (es) |
| MA (1) | MA49374A (es) |
| MX (1) | MX2019014876A (es) |
| PE (1) | PE20200340A1 (es) |
| PH (1) | PH12019502693A1 (es) |
| PL (1) | PL3638680T3 (es) |
| TW (1) | TW201920196A (es) |
| WO (1) | WO2018228934A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3638680T3 (da) * | 2017-06-12 | 2022-09-05 | Boehringer Ingelheim Int | Heteroaromatiske forbindelser som vanininhibitorer |
| CR20210077A (es) | 2018-08-13 | 2021-03-11 | Hoffmann La Roche | Nuevos compuestos heterocíclicos como inhibidores de la monoacilglicerol lipasa |
| WO2020043658A1 (en) | 2018-08-28 | 2020-03-05 | Boehringer Ingelheim International Gmbh | Heteroaromatic compounds as vanin inhibitors |
| MX2021006520A (es) | 2018-12-03 | 2021-07-07 | Boehringer Ingelheim Int | Compuestos heteroaromaticos como inhibidores de vanina. |
| KR20220062515A (ko) | 2019-09-12 | 2022-05-17 | 에프. 호프만-라 로슈 아게 | Magl 억제제로서 4,4a,5,7,8,8a-헥사피리도[4,3-b][1,4]옥사진-3-온 화합물 |
| WO2021174024A1 (en) | 2020-02-28 | 2021-09-02 | First Wave Bio, Inc. | Methods of treating iatrogenic autoimmune colitis |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE602004018811D1 (de) * | 2003-10-09 | 2009-02-12 | Abbott Lab | Pyrrolidinylharnstoffderivate als angiogeneseinhibitoren |
| CA2987179C (en) * | 2015-05-29 | 2020-08-25 | Pfizer Inc. | Heterocyclic compounds as inhibitors of vanin-1 enzyme |
| SG11201811161YA (en) | 2016-07-14 | 2019-01-30 | Pfizer | Novel pyrimidine carboxamides as inhibitors of vanin-1 enzyme |
| DK3638680T3 (da) * | 2017-06-12 | 2022-09-05 | Boehringer Ingelheim Int | Heteroaromatiske forbindelser som vanininhibitorer |
-
2018
- 2018-06-08 DK DK18731766.4T patent/DK3638680T3/da active
- 2018-06-08 BR BR112019021703-7A patent/BR112019021703A2/pt unknown
- 2018-06-08 JP JP2019566724A patent/JP6880243B2/ja active Active
- 2018-06-08 PE PE2019002531A patent/PE20200340A1/es unknown
- 2018-06-08 CA CA3066946A patent/CA3066946A1/en active Pending
- 2018-06-08 EA EA202090014A patent/EA039223B1/ru unknown
- 2018-06-08 ES ES18731766T patent/ES2927021T3/es active Active
- 2018-06-08 PL PL18731766.4T patent/PL3638680T3/pl unknown
- 2018-06-08 AU AU2018285131A patent/AU2018285131B2/en active Active
- 2018-06-08 HU HUE18731766A patent/HUE060597T2/hu unknown
- 2018-06-08 WO PCT/EP2018/065140 patent/WO2018228934A1/en unknown
- 2018-06-08 MA MA049374A patent/MA49374A/fr unknown
- 2018-06-08 US US16/003,252 patent/US10364255B2/en active Active
- 2018-06-08 KR KR1020197038628A patent/KR102607934B1/ko active IP Right Grant
- 2018-06-08 MX MX2019014876A patent/MX2019014876A/es unknown
- 2018-06-08 CN CN201880039562.3A patent/CN110770242B/zh active Active
- 2018-06-08 EP EP18731766.4A patent/EP3638680B1/en active Active
- 2018-06-11 AR ARP180101573A patent/AR112086A1/es unknown
- 2018-06-11 TW TW107119946A patent/TW201920196A/zh unknown
-
2019
- 2019-05-13 US US16/410,037 patent/US20190263828A1/en not_active Abandoned
- 2019-11-28 PH PH12019502693A patent/PH12019502693A1/en unknown
- 2019-12-02 IL IL271104A patent/IL271104B/en unknown
- 2019-12-02 CL CL2019003515A patent/CL2019003515A1/es unknown
- 2019-12-09 CO CONC2019/0013823A patent/CO2019013823A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3638680B1 (en) | 2022-08-10 |
| PE20200340A1 (es) | 2020-02-14 |
| CO2019013823A2 (es) | 2020-01-17 |
| CN110770242A (zh) | 2020-02-07 |
| PL3638680T3 (pl) | 2022-12-19 |
| MX2019014876A (es) | 2020-02-13 |
| CL2019003515A1 (es) | 2020-06-19 |
| JP2020522517A (ja) | 2020-07-30 |
| AU2018285131B2 (en) | 2021-11-11 |
| PH12019502693A1 (en) | 2020-07-13 |
| TW201920196A (zh) | 2019-06-01 |
| HUE060597T2 (hu) | 2023-04-28 |
| CA3066946A1 (en) | 2018-12-20 |
| EP3638680A1 (en) | 2020-04-22 |
| AU2018285131A1 (en) | 2019-10-31 |
| IL271104B (en) | 2022-03-01 |
| US20190263828A1 (en) | 2019-08-29 |
| EA202090014A1 (ru) | 2020-05-12 |
| US20180354968A1 (en) | 2018-12-13 |
| CN110770242B (zh) | 2022-08-19 |
| JP6880243B2 (ja) | 2021-06-02 |
| DK3638680T3 (da) | 2022-09-05 |
| EA039223B1 (ru) | 2021-12-20 |
| KR102607934B1 (ko) | 2023-12-01 |
| WO2018228934A1 (en) | 2018-12-20 |
| BR112019021703A2 (pt) | 2020-05-12 |
| US10364255B2 (en) | 2019-07-30 |
| IL271104A (en) | 2020-01-30 |
| KR20200013718A (ko) | 2020-02-07 |
| ES2927021T3 (es) | 2022-11-02 |
| MA49374A (fr) | 2021-04-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR112086A1 (es) | Compuestos heteroaromáticos como inhibidores de vanina | |
| AR114164A1 (es) | Piridopirimidinonas sustituidas con bencilamino y derivados como inhibidores de sos1 | |
| AR110405A1 (es) | Compuestos | |
| AR112797A1 (es) | Inhibidores de kras g12c y métodos para utilizarlos | |
| AR110400A1 (es) | Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer | |
| AR110922A1 (es) | Compuestos inhibidores del vih | |
| AR107032A1 (es) | Inhibidores bicíclicos de pad4 | |
| AR099228A1 (es) | Inhibidores macrocíclicos de fxia que tienen grupos heterocíclicos | |
| AR103561A1 (es) | Fenilpiridinas herbicidas | |
| AR107488A1 (es) | Compuestos de benzopirazol y análogos de éstos | |
| AR110139A1 (es) | COMPUESTOS MONO Y ESPIROCÍCLICOS QUE CONTIENEN CICLOBUTANO Y AZETIDINA COMO INHIBIDORES DE LA INTEGRINA aV | |
| AR100702A1 (es) | Compuestos inhibidores de quinasa de unión tank | |
| AR110088A1 (es) | Inhibidores de magl | |
| AR104176A1 (es) | Inhibidores de ido (indolamina-2,3-dioxigenasa) | |
| AR095426A1 (es) | Inhibidores tripeptídicos de la epoxicetona proteasa | |
| AR117229A1 (es) | Compuestos heteroaromáticos como inhibidores de vanina | |
| AR107054A1 (es) | DERIVADOS DE ISOINDOL Y COMPOSICIONES FARMACÉUTICAS QUE LOS COMPRENDEN PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR RORg Y RORgt | |
| AR113929A1 (es) | Compuestos heterocíclicos | |
| AR106865A1 (es) | Piridinas sustituidas y métodos de uso | |
| AR106301A1 (es) | Composiciones de pirrolpirimidina como inhibidores de quinasas | |
| AR111494A1 (es) | Compuestos de anilinoquinazolina c₅ y su uso en el tratamiento del cáncer | |
| AR097082A1 (es) | Compuestos terapéuticamente activos y sus métodos de uso | |
| AR107042A1 (es) | Inhibidores de la tirosina quinasa de bruton y métodos de su uso | |
| AR114369A1 (es) | Dinucleótidos cíclicos como agentes antineoplásicos | |
| UY37941A (es) | Derivados de bencimidazol y sus usos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |